Brind.
  1. A company is developing Gozzellix, a next-generation PSMA-PET imaging agent, for prostate cancer treatment, benefiting from Trump-era tariffs and AI stocks.

Strategic research partnership established in the US between TELIX PHARMACEUTICALS LIMITED and United Imaging Healthcare.

1 report, 1 independent Updated Jun 17
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Strategic research partnership established in the US between TELIX PHARMACEUTICALS LIMITED and United Imaging Healthcare.

Who's involved

What this event is mainly about
TELIX PHARMACEUTICALS LIMITED

Keep exploring

Part of

A company is developing Gozzellix, a next-generation PSMA-PET imaging agent, for prostate cancer treatment, benefiting from Trump-era tariffs and AI stocks. All 1 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped